Since your system includes a discrete graphics card which has better performance and is capable of multi-monitor output, the 'onboard' graphics card is disabled by default in the bios and should not normally be used.
bios agent plus key
Note: If there are still problems to get the onboard graphics connections working in Windows , also try changing the 'Primary Display' setting in the bios screenshot below to 'CPU Graphics', but just a reminder that your graphics performance will be affected and you would want to avoid this.
The Allow data recovery agent check box is used to specify whether a data recovery agent can be used with BitLocker-protected operating system drives. Before a data recovery agent can be used, it must be added from Public Key Policies, which is located in the Group Policy Management Console (GPMC) or in the Local Group Policy Editor.
The Allow data recovery agent check box is used to specify whether a data recovery agent can be used with BitLocker-protected fixed data drives. Before a data recovery agent can be used, it must be added from Public Key Policies, which is located in the Group Policy Management Console (GPMC) or in the Local Group Policy Editor.
The Allow data recovery agent check box is used to specify whether a data recovery agent can be used with BitLocker-protected removable data drives. Before a data recovery agent can be used, it must be added from Public Key Policies , which is accessed using the GPMC or the Local Group Policy Editor.
An identification field is required to manage certificate-based data recovery agents on BitLocker-protected drives and for potential updates to the BitLocker To Go Reader. BitLocker manages and updates data recovery agents only when the identification field on the drive matches the value that is configured in the identification field. In a similar manner, BitLocker updates the BitLocker To Go Reader only when the identification field's value on the drive matches the value that is configured for the identification field.
Why we chose it: IXACT Contact was not originally created as a real estate specific CRM, but it does offer a free trial for agents who may be interested in checking out the features. Its most attractive feature may be its ability to integrate your real estate related work into a single location. Other features include email automation, a social stream service that boasts your social media marketing technique, a nice-looking website and excellent customer service.
This is especially handy because HubSpot was not created with real estate agents in mind. So the ability to setup the platform the way it functions best for you goes a long way to making this platform feel more like home for agents who are still learning the ropes.
RealOffice360 beats out the competition because it is more suited to real estate agents. It offers lead profiles that address the topics agents need to know such as whether a contact is prequalified for a loan and how long ago they purchased their home. It is also visually appealing and user friendly.
San Francisco, CA and Suzhou /PRNewswire/ - Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced that the National Medical Products Administration (NMPA) of China has accepted the supplemental New Drug Application (sNDA) for sintilimab plus bevacizumab biosimilar injection and chemotherapy in patients with EGFR-mutated non-squamous non-small cell lung-cancer (nsqNSCLC) who progressed after EGFR-TKI therapy.
The principal investigator of the ORIENT-31 study, Prof. Shun Lu from the Oncology Department of Shanghai Chest Hospital, stated, "In China, the incidence and mortality of lung cancer ranks top among all malignancies, and about 40%-50% nsqNSCLC patients have an EGFR mutation. The standard first-line treatment for patients with advanced EGFR-mutated nsqNSCLC is EGFR-TKI therapy. However, the therapeutic options after progression on EGFR-TKI are limited, representing a large unmet medical need. ORIENT-31 was the first prospective, double-blind Phase 3 study globally to demonstrate the PFS benefit of immunotherapy in combination with antiangiogenic agents and chemotherapy in patients with EGFR-mutated nsqNSCLC who progressed after EGFR-TKI therapy."
About the ORIENT-31 StudyORIENT-31 is a randomized, double-blind, multi-center Phase 3 clinical study conducted in China evaluating sintilimab, with or without bevacizumab biosimilar, combined with chemotherapy (pemetrexed and cisplatin) in patients with EGFR-mutated locally advanced or metastatic nsqNSCLC who have progressed following EGFR TKI treatment (ClinicalTrials.gov, NCT003802240). The primary endpoint is PFS as assessed by BIRRC based on RECIST v1.1. The secondary endpoints include overall survival (OS), PFS as assessed by investigators, ORR and safety.
Patients were randomized in a 1:1:1 ratio to receive sintilimab plus bevacizumab biosimilar combined with pemetrexed and cisplatin (Arm A), sintilimab plus placebo 2 combined with pemetrexed and cisplatin (Arm B), or placebo 1 plus placebo 2 combined with pemetrexed and cisplatin (Arm C). After 4 cycles of combination treatment, patients will receive maintenance treatment of sintilimab plus bevacizumab biosimilar and pemetrexed, sintilimab plus placebo 2 and pemetrexed, placebo 1 plus placebo 2 and pemetrexed, until radiographic disease progression, unacceptable toxicity or any other conditions that required treatment discontinuation. Target accrual is 480 patients. By the data cutoff date of the first interim analysis, 444 patients were enrolled.
About BYVASDA (bevacizumab biosimilar injection)BYVASDA, also known as IBI305, is a bevacizumab biosimilar and a recombinant humanized anti-VEGF monoclonal antibody drug. Vascular endothelial growth factor (VEGF) is an important factor in angiogenesis that is highly expressed by the endothelial cells in most human tumors. An anti-VEGF antibody binds VEGF-A selectively with high affinity and blocks its binding to VEGF-2 receptors on the surface of vascular endothelial cells, thereby inhibiting signaling pathways such as PI3K-Akt/PKB and Ras-Raf-MEK-ERK. BYVASDA produces anti-tumor effects by inhibiting the growth, proliferation and migration of vascular endothelial cells, blocking angiogenesis, reducing vascular permeability, blocking blood supply to tumor tissues, inhibiting the proliferation and metastasis of tumor cells and inducing apoptosis in tumor cells. Since its launch, bevacizumab has been approved for the treatment of patients with multiple malignant tumors globally, including non-small cell lung cancer, metastatic colorectal cancer, glioblastoma, renal cell carcinoma, cervical cancer, and epithelial ovarian, fallopian tube, or primary peritoneal cancer. The efficacy and safety of bevacizumab in these tumor types have been well recognized worldwide.
In China, BYVASDA (bevacizumab biosimilar injection) is approved for indications including advanced non-small cell lung cancer, metastatic colorectal cancer, adult recurrent glioblastoma, and advanced or unresectable hepatocellular carcinoma.
TYVYT (sintilimab injection) is not an approved product in the United States.BYVASDA (bevacizumab biosimilar injection), SULINNO, and HALPRYZA (rituximab biosimilar injection) are not approved products in the United States.TYVYT (sintilimab injection, Innovent)BYVASDA (bevacizumab biosimilar injection, Innovent)HALPRYZA (rituximab biosimilar injection, Innovent)SULINNO (adalimumab biosimilar injection, Innovent)Pemazyre (pemigatinib oral inhibitor, Incyte Corporation). Pemazyre was discovered by Incyte Corporation and licensed to Innovent for development and commercialization in Mainland China, Hong Kong, Macau and Taiwan. 2ff7e9595c
Comentários